Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of OSE-279 alone or with Tedopi in advanced solid tumors, lymphomas, and metastatic non-small cell lung cancer
2024-514826-22-00Phase 2Authorised
- Sponsor
- OSE Immunotherapeutics
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of OSE-279 and Tedopi in Nonhematologic neoplasms, lymphoma and non-small cell lung cancer (NSCLC) (3 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Dose-limiting toxicity and Objective response rate. Planned start Dec 2022; status: authorised.
02
Drugs
OSE-279Tedopi
03
Conditions
Nonhematologic neoplasmslymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514826-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514826-22-00.